Vice President
ITF Therapeutics
Vice President
ITF Therapeutics
Develops and commercializes rare-disease therapies
About This Role:
The Vice President of Regulatory Affairs is a senior leadership role responsible for leading and developing all US regulatory activities for ITF Therapeutics’ rare disease portfolio, including both marketed and pipeline products. This individual will lead US regulatory strategy, manage all FDA interactions, and ensure compliance with relevant regulations and post-market safety reporting requirements. This individual will report to the President, serve as a key member of the executive management team, build and lead a high-performing US Regulatory Affairs organization, and act as a strategic partner to Global Regulatory Affairs.
What You'll Do:
Strategic Leadership
Regulatory Engagement & Compliance
Team Leadership
Cross-Functional Collaboration
Required Skills:
Additional Information:
The base compensation range for this role is: $330,000.00-$370,000.00. Compensation is determined through an analytical approach utilizing a combination of factors including, but not limited to, relevant skills & experience, job location, and internal equity.
Develops and commercializes rare-disease therapies
ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.
Explore more opportunities at ITF Therapeutics